Sunshine Biopharma (SBFM) Income towards Parent Company (2011 - 2026)

Sunshine Biopharma (SBFM) has 14 years of Income towards Parent Company data on file, last reported at -$1.2 million in Q1 2026.

• Quarterly Income towards Parent Company fell 5.43% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.1 million (down 2.69% YoY) and the FY2025 annual result came in at -$6.0 million, down 8.7% from the prior year.
• Income towards Parent Company grew to -$1.2 million in Q1 2026, from -$2.2 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$538872.0 in Q2 2022 to a low of -$23.5 million in Q4 2022.
• A 5-year average of -$2.6 million and a median of -$1.2 million in 2022 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2022 — Income towards Parent Company tumbled 3624.47% — and 2023, when it jumped 94.85%.
• Tracing SBFM's Income towards Parent Company over 5 years: stood at -$23.5 million in 2022, then jumped by 94.85% to -$1.2 million in 2023, then slumped by 109.77% to -$2.5 million in 2024, then gained by 14.89% to -$2.2 million in 2025, then surged by 42.52% to -$1.2 million in 2026.
• The last three Income towards Parent Company figures came in at -$1.2 million (Q1 2026), -$2.2 million (Q4 2025), and -$883820.0 (Q3 2025), per Business Quant data.